University of Verona Hospital Trust
Welcome,         Profile    Billing    Logout  
 4 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tortora, Giampaolo
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Recruiting
2
477
Europe
5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib
Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc.
Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
10/25
12/27
Milella, Michele
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Recruiting
3
1000
Europe, Canada, Japan, RoW
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
09/28
09/29
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
TRIPP-FFX, NCT05466799: FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

Recruiting
2
80
Europe, RoW
FOLFIRINOX chemotherapy, Folinic Acid, 5-FU, Oxaliplatin, Irinotecan, OncoSil™, Phosphorous-32 microparticles
OncoSil Medical Limited
Locally Advanced Pancreatic Cancer
06/25
09/25
AxIn, NCT05817903 / 2022-001150-35: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Recruiting
2
118
Europe
Axitinib, Inlyta, Nivolumab
Consorzio Oncotech, Pfizer
Metastatic Renal Cell Carcinoma
04/26
04/27
KROCUS, NCT05756153: A Study of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting
1/2
45
Europe
GFH925, Cetuximab
Genfleet Therapeutics (Shanghai) Inc.
Advance Non-small Cell Lung Cancer
03/25
08/25
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26

Download Options